Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring

The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For

RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - The weight-loss drug boom has been one of the defining healthcare stories of the decade, and its success has created a second-order opportunity that the drugs…

GLP-1 RAs in CKM management: A Q&A with CORXEL

GLP-1 RA medicine has transformed treatment of metabolic diseases such as obesity and diabetes. We spoke with China's CORXEL about theirs.

GLP-1 users return to in-store shopping

NEW YORK — Nora Nye, 58, is refreshing her wardrobe as she sizes down for the first time in over three decades after losing 80 pounds on weight-loss drug Mounjaro. Earlier this year, the Denver bankruptcy lawyer walked into a…

Medtech Atmo resets valuation, preps to surf the GLP-1 wave

The Melbourne company has been pleasantly surprised by doctors’ interest in its product’s ability to treat side effects in patients taking weight loss drugs.

GLP-1 use could boost risky US plastic surgery demand

Weight-loss drugs are reshaping plastic surgery, with more patients seeking treatment for loose skin and volume loss.

Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring

Apyx Medical (NASDAQ:APYX) is positioning its Renuvion technology and newly launched AYON Body Contouring System to address growing demand for surgical aesthetic procedures, a trend CEO Charlie Goodwin said has been reshaped by the increasing use of GLP-1 weight-loss drugs. Speaking at the Canaccor